Quinacrine and Valproic Acid Synergy for AML Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are limited, particularly for relapsed and resistant cases, and there is a need for new combination therapies, especially for unfit patients and those with ongoing infections, as existing regimens often result in toxic side effects and resistance development.
Innovation Solution
The combination of quinacrine and valproic acid, administered simultaneously, separately, or sequentially, demonstrates synergistic effects in treating AML by inducing apoptosis in cancer cells and inhibiting tumor growth, potentially offering a more effective and less toxic alternative.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapy regimens (such as 7+3 protocol with cytarabine and anthracycline) are used to treat AML, then remission can be achieved in up to 70% of patients, but toxic side effects including myelo-suppression and increased infection risk occur
Solution Approach 1:
The patent combines two existing drugs (quinacrine and valproic acid) that have different mechanisms of action into a single therapeutic regimen. Quinacrine targets DNA and disrupts mitochondrial function, while valproic acid inhibits histone deacetylases and affects epigenetic regulation. This combination approach allows the treatment to achieve anti-leukemic effects through multiple pathways simultaneously, potentially improving remission rates while allowing for lower individual doses of each agent, thereby reducing toxicity.
2Reliability
If intensive chemotherapy is administered to achieve complete remission and eliminate residual disease, then relapse prevention is improved, but the treatment becomes unsuitable for elderly patients and those with comorbidities
Solution Approach 1:
The patent employs parameter changes by utilizing epigenetic modulation through valproic acid's inhibition of histone deacetylases, which alters chromatin structure and gene expression patterns in leukemic cells. This epigenetic approach, combined with quinacrine's mitochondrial targeting, creates a therapeutic mechanism that is fundamentally different from traditional DNA-damaging chemotherapy. The altered mechanism of action allows for effective treatment at lower intensities, expanding eligibility to include elderly patients and those with comorbidities who cannot tolerate conventional intensive regimens.
3Reliability
If combination chemotherapy is used to minimize resistance development, then treatment efficacy is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent merges two drugs with complementary and distinct mechanisms of action: quinacrine, which intercalates into DNA and disrupts mitochondrial membrane potential, and valproic acid, which inhibits histone deacetylases and modifies epigenetic landscapes. By combining these agents, the treatment targets multiple cellular processes simultaneously, creating synergistic anti-leukemic effects that reduce the likelihood of resistance development. The fixed combination format simplifies administration compared to multi-agent chemotherapy regimens.
Data Source
AI summary
The present invention relates to synergistic combinations of quinacrine and valproic acid for the treatment of cancer, preferably acute myeloid leukaemia (AML); and methods of treating cancer using such synergistic combinations.